人乳腺癌组织中GATA3的表达及其临床意义

 目的：探讨乳腺癌组织中转录因子GATA3的表达及其临床意义。方法: 应用免疫组化法检测124例乳腺癌组织中GATA3的表达水平，分析其与临床病理指标的关系，探讨其在预测乳腺癌预后中的意义。结果: GATA3的低表达与雌激素受体（ER）/孕激素受体（PR）阴性、肿瘤高组织学分级、脉管癌栓、p53基因突变等表示预后较差的指标相关（P<005），但与肿瘤大小、人表皮生长因子受体 2（HER-2）表达水平、年龄和淋巴结转移情况无关（P>005）；在全部乳腺癌组织中GATA3阳性表达率为564%，GATA3在luminal型乳腺癌中的表达率为684%，高于非luminal型乳腺癌（326%），且差异有统计学意义（P<005）；全部乳腺癌组织中术后复发风险中危组GATA3阳性率高于复发风险高危组（P<005）。结论: 在乳腺癌组织中GATA3的表达水平与组织的分化水平及肿瘤的生物学特性相关，对指导临床治疗及评估患者的预后研究具有一定的意义。

Expression of GATA3 in human breast cancer tissues and its clinical significance

AIM: To investigate the expression of GATA3 in human breast carcinoma and its clinical significance. METHODS: The expression level of GATA3 in breast cancer tissues from 124 patients was detected by the method of immunohistochemistry and the relationships between GATA3 expression and other clinicopathological factors were analyzed. RESULTS: Low expression of GATA3 in breast cancer tissues was associated with estrogen receptor (ER)/progesterone receptor (PR) negative, high histological tumor grade, p53 mutation and vascular invasion (P<005), but not with age, tumor size,human epidermal growth factor receptor 2 (HER-2) expression and lymph node metastasis (P>005). In all breast cancer tissues, the positive expression rate of GATA3 was 56.4%. The positive expression rate of GATA3 in luminal breast cancer is 684%, higher than that in non-luminal breast cancer (326%, P<005). In all breast cancer tissues, the expression of GATA3 in middle recurrence risk group was higher than that in high recurrence risk group (P<005). CONCLUSION: GATA3 expression in breast cancer is related to differentiation and biological characteristics of the tumor, which can be a factor for evaluation of the treatment and prognosis.